Acumen Pharmaceuticals: Funding, Investors & Team (Oct 2026)
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
Acumen Pharmaceuticals has raised $166M across 2 funding rounds on record, the most recent an undisclosed round of $35.8M announced in Mar 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Acumen Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Acumen Pharmaceuticals Funding Rounds
Acumen Pharmaceuticals raised $130M in an undisclosed round announced in Jul 2023.
2.7 years later, an undisclosed round of $35.8M was announced in Mar 2026.
Acumen Pharmaceuticals Founders and Leadership Team
Contact details for the Acumen Pharmaceuticals team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Acumen Pharmaceuticals Funding Compared to Other Biotechnology Startups
Acumen Pharmaceuticals' latest round of $35.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Acumen Pharmaceuticals in Biotechnology and Carmel
Companies Similar to Acumen Pharmaceuticals
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Acumen Pharmaceuticals Funding FAQs
What does Acumen Pharmaceuticals do?
Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.
How much funding has Acumen Pharmaceuticals raised?
Acumen Pharmaceuticals has raised $166M across 2 rounds on record. The most recent is an undisclosed round of $35.8M announced in Mar 2026.
When did Acumen Pharmaceuticals last raise funding?
Acumen Pharmaceuticals' most recent funding round on record is an undisclosed round of $35.8M, announced in Mar 2026.
Who founded Acumen Pharmaceuticals?
FundedIQ lists Daniel O'connell (Founder), William Goure (Founder) at Acumen Pharmaceuticals.
Where is Acumen Pharmaceuticals headquartered?
Acumen Pharmaceuticals is based in Carmel, Indiana, United States.
How many employees does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals is in the 11-50 employee band.
How does Acumen Pharmaceuticals' funding compare to other Biotechnology startups?
Acumen Pharmaceuticals' latest round of $35.8M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Acumen Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Acumen Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.